Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Masimo to Present in Stifel 2021 Virtual Healthcare Conference


Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 4:00 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusiontm pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNettm in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2021-22 U.S. News and World Report Best Hospitals Honor Roll. Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient's physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOCtm), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVitm (rainbow® PVi), and Oxygen Reserve Index (ORitm). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISAtm Capnography with NomoLine® sampling lines. Masimo's family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPGtm, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automationtm platform, and include Iris® Gateway, iSironatm, Patient SafetyNet, Replicatm, Halo IONtm, UniView®, UniView :60tm, and Masimo SafetyNettm. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of Masimo Corporation


These press releases may also interest you

at 10:50
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company's U.S. Food & Drug...

at 10:47
The FTX Foundation proudly announces financial support for the global expansion of the TOGETHER Trial on the same day that the trial investigators receive the prestigious Trial of the Year Award from the Society for Clinical Trials (SCT) in San...

at 10:46
Apple's visionary founder Steve Jobs once said, "The biggest innovations of the 21st century will be at the intersection of biology and technology."...

at 10:45
The "Dermatology OTC Medications Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Route of Administration, Indication and Distribution Channel" report has been added to ResearchAndMarkets.com's offering. The dermatology...

at 10:41
"Hate always terrorizes. That's the intention. As an African American woman who came of age during the Civil Rights era, I know at heart how hate works to harm some and paralyze or, at least, to immobilize others. But movement is life. It's certainly...

at 10:30
The "Introduction to the In-Vitro Diagnostic Regulation (IVDR) Training Course" conference has been added to ResearchAndMarkets.com's offering. The In-Vitro Diagnostic Regulation (EU) 2017/746, which came into force in May 2017 with a transition...



News published on 11 november 2021 at 09:05 and distributed by: